Compare OPRX & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPRX | PALI |
|---|---|---|
| Founded | 2006 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.5M | 268.6M |
| IPO Year | N/A | N/A |
| Metric | OPRX | PALI |
|---|---|---|
| Price | $13.36 | $1.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $14.83 | ★ $16.00 |
| AVG Volume (30 Days) | 221.9K | ★ 4.9M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $109,506,000.00 | N/A |
| Revenue This Year | $19.77 | N/A |
| Revenue Next Year | $11.33 | N/A |
| P/E Ratio | $7,312.30 | ★ N/A |
| Revenue Growth | ★ 24.18 | N/A |
| 52 Week Low | $3.99 | $0.53 |
| 52 Week High | $22.25 | $3.30 |
| Indicator | OPRX | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 34.62 | 50.77 |
| Support Level | $13.14 | $1.73 |
| Resistance Level | $14.95 | $2.27 |
| Average True Range (ATR) | 0.66 | 0.19 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 14.05 | 47.26 |
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.